Celebrating a year of investment and exciting development
Today marks the one year anniversary since Kibion was acquired by a team of Swedish business developers and thus we are celebrating this first year and its exciting development.
Investments in the future by the company’s new owners have resulted in the launch of the “state-of-the-art” C13 platform Kibion® Dynamic, a modern, fully-flexible instrument for rapid and reliable diagnosis of Helicobacter pylori infections.
In Germany the subsidiary Kibion GmbH has moved to new premises, in Bremen, more suited for the business. The commercial team in Germany has also been expanded to meet the increased demand of Kibion’s products from our customers.
Throughout the year we have also invested in global positions at the company headquarters in Sweden to strengthen our commercial capabilities and distribution support.
In February, Kibion successfully completed the transfer of production of Diabact® UBT tablets from the previous owner Orexo’s facilities in Sweden to the CMO company Idifarma in Spain. All the dedicated persons involved in this strategic decision and change contributed to a smooth transfer. The production at the new venue is now up and running as planned which will contribute to Kibion’s current and future operation and growth.
Although we access leading knowledge and expertise in our area, it is important for Kibion to stay focused and be open minded for new opportunities to continue the evolution path in the year’s to come. To accelerate, we would like to further strengthen the ongoing partnerships – but also to find new partners – enabling us to speed up and together make real footprints in the future market. This is important to us, since we are committed to live our vision “To be first in mind, first in choice.”